北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients
作者: Gao, Jing; Wang, Ting-ting; Yu, Jing-wei; Li, Yan-yan; Shen, Lin
关键词: KRAS ; BRAF ; Mutation ; Cetuximab ; Colorectal cancer
刊名: CHINESE JOURNAL OF CANCER RESEARCH
发表日期: 2011-12-01
DOI: 10.1007/s11670-011-0271-4
卷: 23, 期:4, 页:271-275
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: GROWTH-FACTOR RECEPTOR ; PLUS IRINOTECAN ; PTEN EXPRESSION ; MUTATIONS ; TUMORS ; TUMORIGENESIS ; ONCOGENES ; BENEFIT
英文摘要:

To analyze the relationship between KRAS, BRAF mutations and the response to Cetuximab in Chinese colorectal cancer patients.

A total of 273 Chinese colorectal cancer patients were evaluated for KRAS and BRAF mutations by Sanger sequencing. Among them, 59 patients with metastatic colorectal cancer (mCRC) were treated with Cetuximab in combination with chemotherapy from August 2005 to July 2009. Statistical analysis was conducted to assess the relationship between KRAS, BRAF mutations and the response or survival of 59 mCRC patients.

KRAS and BRAF mutation rates were 38.5% (105/273) and 5.1% (14/273), respectively, and KRAS/BRAF mutations were mutually exclusive. Among 59 patients treated with Cetuximab plus chemotherapy, KRAS and BRAF mutations were identified in 11 and 5 patients, respectively. The response rates and median progression-free survivals (PFS) in KRAS wild-type and mutant patients were 35.4% (17/48) vs. 9.1% (1/11) (P=0.054) and 153 days vs. 99 days (P=0.01), respectively. Also, the response rates and median PFS in BRAF wild-type and mutant patients were 37.2% (16/43) vs. 20% (1/5) (P=0.016) and 138 days vs. 90 days (P=0.036), respectively.

Besides KRAS, assessing BRAF mutation should also be required to select patients eligible for Cetuximab. Further prospective evaluation in large samples should be performed to confirm these preliminary findings.

语种: 英语
WOS记录号: WOS:000298356300005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56310
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Gastrointestinal On, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Gao, Jing,Wang, Ting-ting,Yu, Jing-wei,et al. Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients[J]. CHINESE JOURNAL OF CANCER RESEARCH,2011,23(4):271-275.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Gao, Jing]'s Articles
[Wang, Ting-ting]'s Articles
[Yu, Jing-wei]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Gao, Jing]‘s Articles
[Wang, Ting-ting]‘s Articles
[Yu, Jing-wei]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace